Dement Neurocogn Disord.  2019 Jun;18(2):33-46. 10.12779/dnd.2019.18.2.33.

A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation

Affiliations
  • 1Department of Neurology, Hanyang University College of Medicine, Seoul, Korea. kimsh1@hanyang.ac.kr
  • 2Department of Neurology, Konkuk University School of Medicine, Seoul, Korea.
  • 3Department of Laboratory Medicine, Hanyang University College of Medicine, Seoul, Korea.
  • 4Stem Cell Neuroplasticity Research Group, Kyungpook National University, Daegu, Korea.
  • 5Department of Physiology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Korea.
  • 6Department of Laboratory Animal Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu, Korea.

Abstract

Alzheimer's disease (AD), the most common form of dementia, has emerged as a major global public health challenge. However, the complexity of AD in its biological, genetic, and clinical aspects has hindered the development of effective therapeutic agents. Research plans that integrate new drug discoveries are urgently needed, including those based on novel and reliable biomarkers that reflect not only clinical phenotype, but also genetic and neuroimaging information. Therapeutic strategies such as stratification (i.e., subgrouping of patients having similar clinical characteristics or genetic background) and personalized medicine could be set as new directions for developing effective drugs for AD. In this review, we describe a therapeutic strategy that is based on immune-inflammation modulation for a subgroup of AD and related dementias, arguing that the use of stratification and personalized medicine is a promising way to achieve targeted medicine. The Korean AD Research Platform Initiative based on Immune-Inflammatory biomarkers (K-ARPI) has recently launched a strategy to develop novel biomarkers to identify a subpopulation of patients with AD and to develop new drug candidates for delaying the progression of AD by modulating toxic immune inflammatory response. Sphingosine kinase 1 (SphK1) and its metabolites, triggering receptor expressed on myeloid cells-2 (TREM2) related signals, and actin motility related proteins including Nck-associated protein 1 (Nap1) were selected as promising targets to modulate neuroinflammation. Their roles in stratification and personalized medicine will be discussed.

Keyword

Alzheimer's Disease; Inflammation; Personalized Medicine; Biomarkers

MeSH Terms

Actins
Alzheimer Disease*
Biomarkers
Dementia
Humans
Inflammation
Neuroimaging
Phenotype
Phosphotransferases
Precision Medicine
Public Health
Sphingosine
Actins
Biomarkers
Phosphotransferases
Sphingosine
Full Text Links
  • DND
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error